Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

Image: Navitor Pharmaceuticals has commenced phase 1 clinical evaluation of NV-5138 for treatment-resistant depression. Photo: courtesy of everydayplus / FreeDigitalPhotos.net.